Search Result

Results for "

Ras

" in MCE Product Catalog:

By Targets:	Ras (88) Akt (1) Aminoacyl-tRNA Synthetase (1) Angiotensin Receptor (3) Angiotensin-converting Enzyme (ACE) (3) Antibiotic (1) Apoptosis (19) Autophagy (4) DNA/RNA Synthesis (1) EGFR (1) Endogenous Metabolite (9) ERK (6) Farnesyl Transferase (16) Ferroptosis (2) Fungal (1) Glutathione Peroxidase (1) HDAC (2) Histone Demethylase (2) MAGL (1) MAPKAPK2 (MK2) (1) MDM-2/p53 (1) MEK (3) MMP (1) NOD-like Receptor (NLR) (1) p38 MAPK (1) Phosphodiesterase (PDE) (4) Phospholipase (1) PI3K (1) PROTAC Linkers (3) PROTACs (2) Raf (7) ROS Kinase (1) SHP2 (1) Target Protein Ligand-Linker Conjugates (6) Tyrosinase (1) VDAC (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (135) Cardiovascular Disease (7) Endocrinology (2) Infection (7) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (2)

By Targets:

Ras (88)

Akt (1)

Aminoacyl-tRNA Synthetase (1)

Angiotensin Receptor (3)

Angiotensin-converting Enzyme (ACE) (3)

Antibiotic (1)

Apoptosis (19)

Autophagy (4)

DNA/RNA Synthesis (1)

EGFR (1)

Endogenous Metabolite (9)

ERK (6)

Farnesyl Transferase (16)

Ferroptosis (2)

Fungal (1)

Glutathione Peroxidase (1)

HDAC (2)

Histone Demethylase (2)

MAGL (1)

MAPKAPK2 (MK2) (1)

MDM-2/p53 (1)

MEK (3)

MMP (1)

NOD-like Receptor (NLR) (1)

p38 MAPK (1)

Phosphodiesterase (PDE) (4)

Phospholipase (1)

PI3K (1)

PROTAC Linkers (3)

PROTACs (2)

Raf (7)

ROS Kinase (1)

SHP2 (1)

Target Protein Ligand-Linker Conjugates (6)

Tyrosinase (1)

VDAC (1)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (135)

Cardiovascular Disease (7)

Endocrinology (2)

Infection (7)

Inflammation/Immunology (9)

Metabolic Disease (2)

Neurological Disease (2)

148

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: Ras

Cat. No.	Product Name	Target	Research Areas

HY-138294

RAS/RAS-RAF-IN-1	Ras Raf	Cancer
RAS/RAS-RAF-IN-1 is a potent *RAS* and *RAS-RAF* inhibitor. RAS/RAS-RAF-IN-1 has a K_D of 5.0 μΜ-15 μΜ for cyclophilin A (CYPA) binding affinity. RAS/RAS-RAF-IN-1 has antitumor activity.

HY-148878

Ras modulator-1
Ras Cancer

Ras modulator-1 is a modulator of Ras. Ras modulator-1 is an active compound extracted from patent US20120302581.

Ras modulator-1	Ras	Cancer
Ras modulator-1 is a modulator of *Ras. Ras* modulator-1 is an active compound extracted from patent US20120302581.

HY-122862

RAS inhibitor Abd-7	Ras	Cancer
RAS inhibitor Abd-7, a potent RAS-binding compound (K_d=51 nM), is a RAS-effector protein-protein interaction (PPI) inhibitor. RAS inhibitor Abd-7 interacts with RAS inside the cells, prevents RAS-effector interactions and inhibits endogenous RAS-dependent signaling. RAS inhibitor Abd-7 impairs the PPI of various mutant KRAS proteins with PI3K, CRAF and RALGDS as well as NRAS Q61H and HRAS G12V.

HY-148439

RAS-IN-2
Ras Cancer

RAS-IN-2 (Compound A122) is a potent RAS(ON) MULTI inhibitor and can be used for the research of cancer.

RAS-IN-2	Ras	Cancer
RAS-IN-2 (Compound A122) is a potent RAS(ON) MULTI inhibitor and can be used for the research of cancer.

HY-129189

RAS GTPase inhibitor 1	Ras	Cancer
RAS GTPase inhibitor 1 (example 51) is a RAS GTPase inhibitor with anti-tumor activity, extracted from patent WO2018212774A1. RAS GTPase inhibitor 1 (example 51) exhibits an EC₅₀ less than 1 μM for at least one nucleotide exchange and an IC₅₀ less than 1 μM in H727 cells.

HY-14718

Resminostat Ras2410; 4SC-201	HDAC	Cancer
Resminostat (RAS2410; 4SC-201) is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC₅₀ values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-121532

(-)-Rasfonin	Ras Apoptosis Autophagy	Cancer
(-)-Rasfonin is a fungal secondary metabolite and inhibits small G proteins Ras. (-)-Rasfonin induces apoptosis, necrosis and autophagy in ACHN cells (a renal carcinoma cell line).

HY-139950

Rasarfin
Ras Cancer

Rasarfin is a dual Ras and ARF6 inhibitor.

Rasarfin	Ras	Cancer
Rasarfin is a dual *Ras* and ARF6 inhibitor.

HY-14718A

Resminostat hydrochloride Ras2410 hydrochloride; 4SC-201 hydrochloride	HDAC	Cancer
Resminostat hydrochloride is a potent inhibitor of HDAC1, HDAC3 and HDAC6, with mean IC₅₀ values of 42.5, 50.1, 71.8 nM, respectively, and shows less potent activities against HDAC8, with an IC₅₀ of 877 nM.

HY-18674

*K-Ras-IN-1*	Ras	Cancer
K-Ras-IN-1 is a *K-Ras* inhibitor. K-Ras-IN-1 binds to K-Ras (WT), K-Ras (G12D), K-Ras (G12V), and H-Ras. K-Ras-IN-1 has potential for the research of pancreatic, colon and lung carcinomas.

HY-101295

Pan-RAS-IN-1
Ras Cancer

Pan-RAS-IN-1 is a pan-Ras inhibitor that disrupts the interaction of Ras proteins and their effectors.

*Pan-RAS-IN-1*	Ras	Cancer
Pan-RAS-IN-1 is a *pan-Ras* inhibitor that disrupts the interaction of Ras proteins and their effectors.

HY-115555

*K-Ras-PDEδ-IN-1*	Phosphodiesterase (PDE)	Cancer
K-Ras-PDEδ-IN-1 is a novel and potent competitive *K-Ras-PDEδ* inhibitor. K-Ras-PDEδ-IN-1 binds to the farnesyl binding pocket of PDEδ with a low nanomolar K_d of 8 nM.

HY-129523

*PROTAC K-Ras* Degrader-1**	PROTACs Ras	Cancer
PROTAC K-Ras Degrader-1 (Compound 518) is a PROTAC. PROTAC K-Ras Degrader-1 can effectively degrades *K-Ras* based on Cereblon E3 ligand, exhibits ≥70% degradation efficacy in SW1573 cells.

HY-18605

K-Ras G12C-IN-2
Ras Cancer

K-Ras G12C-IN-2 is an irreversible covalent K-Ras G12C inhibitor.

*K-Ras* G12C-IN-2**	Ras	Cancer
K-Ras G12C-IN-2 is an irreversible covalent *K-Ras* G12C** inhibitor.

HY-129776

*K-Ras* ligand-Linker Conjugate 2**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 2 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 2 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-129775

*K-Ras* ligand-Linker Conjugate 1**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 1 incorporates a ligand for *K-Ras, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras* ligand-Linker Conjugate 1 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-18606

K-Ras G12C-IN-3
Ras Cancer

K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

*K-Ras* G12C-IN-3**	Ras	Cancer
K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

HY-130822

*K-Ras* ligand-Linker Conjugate 4**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 4 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 4 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130823

*K-Ras* ligand-Linker Conjugate 5**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 5 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 5 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130991

*K-Ras* ligand-Linker Conjugate 6**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 6 incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 6 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-130707

*K-Ras* ligand-Linker Conjugate 3**	Target Protein Ligand-Linker Conjugates	Cancer
K-Ras ligand-Linker Conjugate 3 (Compound 001371) incorporates a ligand for K-Ras recruiting moiety, and a PROTAC linker, which recruit E3 ligases (such as VHL, CRBN, MDM2, and IAP). K-Ras ligand-Linker Conjugate 3 can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523), which is potent PROTAC K-Ras degrader that exhibits ≥70% degradation efficacy in SW1573 cells.

HY-128044

Ftase inhibitor I B581	Farnesyl Transferase	Cancer
Ftase inhibitor I (B581) is a potent, selective and peptidomimetic farnesyl transferase (FTase) inhibitor. Ftase inhibitor I shows selectivity for FTase over geranylgeranyl isoprenoid (Ras-GG) or the fatty acid myristate (Myr-Ras).

HY-18604

K-Ras G12C-IN-1
Ras Cancer

K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.
HY-12446

K-Ras(G12C) inhibitor 9
Ras Cancer

K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C).

*K-Ras* G12C-IN-1**	Ras	Cancer
K-Ras G12C-IN-1 is a novel and irreversible inhibitor of mutant K-ras G12C extracted from patent WO 2014152588 A1.

*K-Ras(G12C) inhibitor 9*	Ras	Cancer
K-Ras (G12C) inhibitor 9 is an allosteric inhibitor of the K-Ras (G12C).

HY-18707

*K-Ras(G12C) inhibitor 12*	Ras Apoptosis	Cancer
K-Ras(G12C) inhibitor 12 is a K-Ras(G12C) inhibitor, the half-maximum effective concentration (EC50) for K-Ras(G12C) inhibitor 12 in H1792 cells is 0.32 μM.

HY-107841

K-Ras(G12C) inhibitor 6
Ras Cancer

K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the K-Ras(G12C).
HY-124306

ML-099
CID-888706
Ras Cancer

ML-099 (CID-888706) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, Rab7, and Rab-2A.

*K-Ras(G12C) inhibitor 6*	Ras	Cancer
K-Ras(G12C) inhibitor 6 is an irreversible, allosteric inhibitor of the *K-Ras(G12C)*.

ML-099 CID-888706	Ras	Cancer
ML-099 (CID-888706) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, *Ras, Rab7, and Rab-2A*.

HY-123673

MCP110	Ras Raf	Cancer
MCP110 is an inhibitor of *Ras/Raf-1* interaction. MCP110 blocks the interaction of Ras with Raf. MCP110 disrupts this interaction might can be used for the research of human tumors.

HY-128771

K-Ras G12C-IN-4
Ras Cancer

K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS^G12C.
HY-147229

GDC-6036-NH
Ras Cancer

GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a RAS inhibitor and can be used in cancer research.

*K-Ras* G12C-IN-4**	Ras	Cancer
K-Ras G12C-IN-4, compound 1, is a potent Covalent Inhibitor of KRAS^G12C.

GDC-6036-NH	Ras	Cancer
GDC-6036-NH is from patent WO2020097537A2, and a precursor of compound 17 a/b. Compound 17 a/b is a *RAS* inhibitor and can be used in cancer research.

HY-W048303

L-Azatyrosine	Antibiotic	Cancer Infection
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes.

HY-111671

SOS1 activator 1	Ras	Cancer
SOS1 activator 1 (Compound 64) is a potent activator of SOS1-mediated nucleotide exchange with a K_d of 44 nM. SOS1 is a guanine nucleotide exchange factor that catalyzes the exchange of GDP for GTP on RAS.

HY-151566

Antifungal agent 46	Ras Farnesyl Transferase Fungal	Infection
Antifungal agent 46 (compound 2f) is a potent antifungal agent. Antifungal agent 46 prevents *Ras* signaling by inhibiting protein farnesyltransferase.

HY-136579

ERK-IN-3	ERK	Cancer
ERK-IN-3 is a potent and orally active inhibitor of ERK. ERK-IN-3 inhibits ERK1/2 with low single-digit nM IC₅₀ values. ERK-IN-3 can be used for the research of cancers driven by RAS mutations.

HY-136579A

ERK-IN-3 benzenesulfonate	ERK	Cancer
ERK-IN-3 benzenesulfonate is a potent and orally active inhibitor of ERK. ERK-IN-3 benzenesulfonate inhibits ERK1/2 with low single-digit nM IC₅₀ values. ERK-IN-3 benzenesulfonate can be used for the research of cancers driven by RAS mutations.

HY-16059

Arglabin (+)-Arglabin	NOD-like Receptor (NLR) Farnesyl Transferase Autophagy	Cancer Inflammation/Immunology
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene.

HY-124944

APS6-45
Ras Cancer

APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.

APS6-45	Ras	Cancer
APS6-45 is an orally active tumor-calibrated inhibitor (TCI). APS6-45 inhibits RAS/MAPK signaling and exhibits antitumor activity.

HY-142452

Pan-RAF kinase inhibitor 1	Raf	Cancer
Pan-RAF kinase inhibitor 1 is a potent inhibitor of Pan-RAF kinase. Pan-RAF kinase inhibitor 1 regulates MAPK signaling by inhibiting RAF kinase, thereby exerting an effect on the proliferation of RAS-mutant tumor cells. Pan-RAF kinase inhibitor 1 has the potential for the research of cancer diseases (extracted from patent WO2021110141A1, compound 16B).

HY-152774

Antitumor agent-86	Akt PI3K	Cancer
Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC₅₀ value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting *RAS/PI3K/Akt/JNK* signaling cascades.

HY-14754

Salirasib S-Farnesylthiosalicylic acid; Farnesyl Thiosalicylic Acid; FTS	Ras Autophagy	Cancer
Salirasib is a *Ras* inhibitor that inhibits specifically both oncogenically activated Ras and growth factor receptor-mediated Ras activation, resulting in the inhibition of Ras-dependent tumor growth.

HY-123242

FTI-2153	Farnesyl Transferase	Cancer
FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity.

HY-123242A

FTI-2153 TFA	Farnesyl Transferase	Cancer
FTI-2153 TFA is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 TFA is >3000-fold more potent at blocking H-Ras (IC₅₀, 10 nM) than Rap1A processing. Anti-cancer activity.

HY-12403A

Angiotensin (1-7) (acetate) Ang-(1-7) (acetate)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Endocrinology Inflammation/Immunology Cardiovascular Disease
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Metabolic Disease Cardiovascular Disease
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Neurological Disease Cancer
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-19539

NSC-658497	Ras	Cancer
NSC-658497 is an effective inhibitor of Ras-GEF, SOS1. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation.

HY-15879

LB42708	Farnesyl Transferase Apoptosis	Inflammation/Immunology
LB42708 is a potent, selective and orally active farnesyltransferase inhibitor. LB42708 inhibits farnesylation of *H-Ras, N-Ras* and *K-Ras4B* with IC₅₀s of 0.8 nM, 1.2 nM and 2.0 nM, respectively.

HY-15136

Lonafarnib Sch66336	Farnesyl Transferase Ras Autophagy	Cancer Infection
Lonafarnib (Sch66336) is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of *H-ras, K-ras* and *N-ras* with IC₅₀ values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.

HY-114398

BAY-293	Ras	Cancer
BAY-293, a valuable chemical probe, blocks *RAS* activation via disruption of the KRAS-SOS1 interaction with an IC₅₀ of 21 nM. BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1). SOS1 is the guanine nucleotide exchange factor (GEF) and activator of RAS.

HY-107753

XRP44X	Ras	Cancer Inflammation/Immunology
XRP44X inhibits *Ras*-induced transcription activation with the IC₅₀ of 10 nM. XRP44X inhibits activation of the Ras-Erk-1/2 pathway by FGF-2. XRP44X is an inhibitor of Ras/Erk activation of Elk3 that also affects microtubules.

HY-15716

Kobe0065	Ras Apoptosis	Cancer
Kobe0065 is a novel and effective inhibitor of Ras-Raf interaction, competitively inhibiting the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i value of 46±13 μM.

HY-15136B

(Rac)-Lonafarnib Sch66336 racemate	Farnesyl Transferase	Cancer Infection
(Rac)-Lonafarnib (Sch66336 racemate) is the racemate of Lonafarnib. Lonafarnib is a potent and orally active farnesyl transferase (FTase) inhibitor. Lonafarnib inhibits the activities of *H-ras, K-ras* and *N-ras* with IC₅₀ values of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib also has anti-hepatitis delta virus (HDV) activities.

HY-124514

UC-857993	Ras ERK	Cancer
UC-857993 is a selective *SOS1-Ras* inhibitor (K_d=14.7 μM, His₆-SOS1_cat), suppressing catalytic activity. UC-857993 also inhibits ERK and *Ras* activation, suppresses the growth of mouse embryonic fibroblasts (MEFs).

HY-118208

ML-097
CID-2160985
Ras Cancer

ML-097 (CID-2160985) is a pan Ras-related GTPases activator that can activate Rac1, cell division cycle 42, Ras, and Rab7.
HY-P3277

KRpep-2d
Ras Cancer

KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research.
HY-15717

Kobe2602
Ras Cancer

Kobe2602 is a Ras-Raf interaction inhibitor. Kobe2602 inhibits the binding of H-Ras·GTP to c-Raf-1 RBD with a K_i of 149 μM. Kobe2602 has antitumor activity.
HY-P3277A

KRpep-2d TFA
Ras Cancer

KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research.

HY-15872A

FTI-277 hydrochloride	Farnesyl Transferase Apoptosis Ras	Cancer Infection
FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras* oncogenic signaling. FTI-277 hydrochloride can inhibit hepatitis delta virus (HDV)** infection.

HY-15872

FTI-277	Farnesyl Transferase Apoptosis Ras	Cancer Infection
FTI-277 is an inhibitor of farnesyl transferase (FTase); a highly potent Ras CAAX peptidomimetic which antagonizes both H- and *K-Ras* oncogenic signaling. FTI-277 can inhibit hepatitis delta virus (HDV)** infection.

HY-16373

CP-609754 LNK-754; OSI-754	Farnesyl Transferase	Cancer
CP-609754 (LNK-754) is a potent and reversible farnesyltransferase inhibitor with potential anticancer activity.The IC₅₀ for inhibiting farnesylation of recombinant human H-Ras is 0.57 ng/mL and recombinant K-Ras is 46 ng/mL.

HY-134885

RMC-0331 RM-023	SHP2 Ras	Cancer
RMC-0331 (RM-023) is a potent, selective and orally bioavailable SOS1 inhibitor. RMC-0331 is an in vivo tool compound that blocks RAS activation via disruption of the RAS-SOS1 interaction.

HY-150926

G12Si-1	Ras	Cancer
G12Si-1 is a selective *K-Ras(G12S)* covalent inhibitor, which can inhibit oncogenic signaling of *K-Ras(G12S). G12Si-1 shows good ability to covalently engage recombinant K-Ras(G12S)* at the mutant serine residue. G12Si-1 can also affect nucleotide cycling of K-Ras by blocking Sos-catalyzed exchange and decreasing the rate of EDTA promoted exchange.

HY-N6674

Diazepinomicin ECO-4601; TLN-4601; BU 4664L	Ras Apoptosis	Cancer
Diazepinomicin (TLN-4601) is a secondary metabolite produced by Micromonospora sp. Diazepinomicin (TLN-4601) inhibits the EGF-induced Ras-ERK MAPK signaling pathway and induces apoptosis. An anti-tumor agent for K-Ras mutant models.

HY-14947

Balamapimod
MKI 833
MEK Cancer

Balamapimod (MKI 833) is a reversible Ras/Raf/MEK inhibitor with potential anti-tumor activity.
HY-12408

6H05
Ras Cancer

6H05 is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
HY-12656

SCH 51344
Ras Cancer

SCH 51344 inhibits Ras induced malignant transformation and prevents anchorage-independent growth of oncogene transformed fibroblasts.
HY-12408A

6H05 (TFA)
Ras Cancer

6H05 TFA is a selective, and allosteric inhibitor of oncogenic mutant K-Ras(G12C).
HY-13497

STK33-IN-1
Others Cancer

STK33-IN-1 (compound 1) is a STK33 inhibitor, with an IC₅₀ of 7 nM.
HY-151288

KRAS inhibitor-21
Ras Cancer

KRAS inhibitor-21 (22b) is a KRAS G12C inhibitor with an IC₅₀ value of <0.01 μM. KRAS inhibitor-21 can be used in cancer research.
HY-145915A

(E/Z)-ZINC09659342
Ras Cancer

(E/Z)-ZINC09659342 is an inhibitor of Lbc-RhoA interaction.
HY-145915

ZINC09659342
Ras Cancer

ZINC09659342 (compound 13) is an inhibitor of Lbc-RhoA interaction with an IC₅₀ of 3.6 μΜ.
HY-13452

CID-1067700
ML282
Ras Inflammation/Immunology

CID-1067700 (ML282) is a pan GTPase inhibitor, and competitively inhibits Ras-related in brain 7 (Rab7) with a K_i of 13 nM.
HY-18997

PLX7904
PB04
Raf Cancer

PLX7904 is a potent and selective BRAF inhibitor, with IC₅₀ of appr 5 nM against BRAF^V600E in mutant RAS expressing cells.

HY-128553

Antineoplaston A10	Ras Apoptosis Endogenous Metabolite	Cancer
Antineoplaston A10, a naturally occurring substance in human body, is a *Ras* inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-U00416

ARS-1323
Ras Cancer

ARS-1323, the racemate of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.

HY-128553A

(Rac)-Antineoplaston A10	Ras Apoptosis	Cancer
(rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a *Ras* inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-N6796

Manumycin A	Farnesyl Transferase Ras Apoptosis Phospholipase	Cancer Infection
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the *Ras* protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A is a nSMase inhibitor (EC₅₀=0.25 μM).

HY-116514

(S)-(−)-Perillyl alcohol	Apoptosis Endogenous Metabolite	Cancer
(S)-(−)-Perillyl alcohol is a monoterpene found in lavender, inhibits farnesylation of Ras, upregulates the mannose-6-phosphate receptor and induces apoptosis. Anti-cancer activity.

HY-102028

KY1220	Wnt β-catenin	Cancer
KY1220 is a compound that destabilizes both β-catenin and Ras, via targeting the Wnt/β-catenin pathway; with an IC₅₀ of 2.1 μM in HEK293 reporter cells.

HY-U00417

ARS-1630
Ras Cancer

ARS-1630, a less active enantiomer of ARS-1620, is a novel inhibitor of mutant K-ras G12C extracted from patent WO 2015054572 A1.
HY-130819

Tos-PEG4-THP
PROTAC Linkers Cancer

Tos-PEG4-THP is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523).

HY-113313S2

Aldosterone-d4	Endogenous Metabolite	Cardiovascular Disease
Aldosterone-d₄ is the deuterium labeled Aldosterone. Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by t

HY-100002

ML162	Glutathione Peroxidase Ferroptosis	Cancer
ML162 is a covalent glutathione peroxidase 4 (GPX4) inhibitor. ML162 has a selective lethal effect on mutant RAS oncogene-expressing cell lines

HY-15871

GGTI298 Trifluoroacetate	Ras Apoptosis	Cancer
GGTI298 Trifluoroacetate is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, which can inhibit Rap1A with IC₅₀ of 3 μM; little effect on *Ha-Ras* with IC₅₀ of >20 μM.

HY-P3108

Alamandine	Angiotensin Receptor Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions.

HY-N1374

Magnolin	ERK	Inflammation/Immunology
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-117935

GGTI-286 hydrochloride	Ras	Cancer
GGTI-286 hydrochloride, a potent GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 hydrochloride selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s =2 and >30 μM, respectively). GGTI-286 hydrochloride also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-100876

GGTI298	Ras Apoptosis	Cancer
GGTI298 is a CAAZ peptidomimetic geranylgeranyltransferase I (GGTase I) inhibitor, strongly inhibiting the processing of geranylgeranylated Rap1A with little effect on processing of farnesylated Ha-Ras, with IC₅₀ values of 3 and > 20 μM in vivo, respectively.

HY-115489

GGTI-286	Ras	Cancer
GGTI-286, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-130821

THP-PEG4-Pyrrolidine(N-Me)-CH2OH	PROTAC Linkers	Cancer
THP-PEG4-Pyrrolidine(N-Me)-CH2OH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523).

HY-16662

Oncrasin-1	Ras Apoptosis	Cancer
Oncrasin-1 is a potent and effective anticancer inhibitor that kills various human lung cancer cells with K-Ras mutations at low or submicromolar concentrations; also led to abnormal aggregation of PKCι in nucleus of sensitive cells but not in resistant cells.

HY-130820

THP-PEG4-Pyrrolidine(N-Boc)-CH2OH	PROTAC Linkers	Cancer
THP-PEG4-Pyrrolidine(N-Boc)-CH2OH is a PEG-based PROTAC linker can be used in the synthesis of PROTAC K-Ras Degrader-1 (HY-129523).

HY-12875

BQU57	Ras	Cancer
BQU57 shows selective inhibition for Ral relative to Ras or Rho and inhibit xenograft tumor growth similar to depletion of Ral by siRNA. The IC50 for BQU57 of 2.0 μM in H2122 and 1.3 μM in H358.

HY-142161

ABD957	MAGL	Cancer
ABD957 is a potent and selective covalent inhibitor of the ABHD17 family of depalmitoylases, with an IC₅₀ of 0.21 µM for ABHD17B. ABD957 can block N-Ras signaling and the growth of NRAS-mutant AML cells.

HY-115489A

GGTI-286 TFA	Ras	Cancer
GGTI-286 TFA, a potent and cell-permeable GGTase I inhibitor, is 25-fold more potent (IC₅₀=2 μM) than the corresponding methyl ester of FTI-276 (HY-15873A). GGTI-286 TFA selectively inhibits geranylgeranylation of Rap1A over farnesylation of H-Ras in NIH3T3 cells (IC₅₀s=2 and >30 μM, respectively). GGTI-286 TFA also potently inhibits oncogenic K-Ras4B stimulation with an IC₅₀ of 1 μM.

HY-135967

MTH1-IN-2	DNA/RNA Synthesis	Cancer
MTH1-IN-2 is a MutT homolog 1 (MTH1) inhibitor extracted from patent WO2016135138A1, Compound (6), MTH1-IN-2 can be used for the research of cancer. Anti-tumor activity.

HY-122641

Deltasonamide 1	Phosphodiesterase (PDE)	Cancer
Deltasonamide 1 is a PDE6δ-KRas inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a K_D of 203 pM. Deltasonamide 1 can be used for the research of tumors.

HY-122641D

Deltasonamide 1 TFA	Phosphodiesterase (PDE)	Cancer
Deltasonamide 1 TFA is a PDE6δ-KRas inhibitor. Deltasonamide 1 can inhibit PDE6δ-KRas with a K_D of 203 pM. Deltasonamide 1 can be used for the research of tumors.

HY-117149

MLS000532223	Ras	Cancer
MLS000532223 is a high affinity, selective inhibitor of Rho family GTPases, with EC₅₀ values ranging from 16 μM to 120 μM. MLS000532223 prevents GTP binding to several GTPases.

HY-108436

Deltazinone 1	Phosphodiesterase (PDE)	Cancer
Deltazinone 1, a pyrazolopyridazinone, is a highly selective PDEδ inhibitor with a K_D of 8 nM. Deltazinone 1 inhibits the PDEδ-Ras interaction. Deltazinone 1 shows a dose-dependent inhibitory response on proliferation in oncogenic KRas-dependent cell lines.

HY-113313

Aldosterone	Endogenous Metabolite	Cardiovascular Disease
Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level.

HY-50846

SCH772984	ERK	Cancer
SCH772984 is a highly selective and ATP-competitive ERK inhibitor, with IC₅₀s of 4 and 1 nM for ERK1 and ERK2, respectively. SCH772984 has antitumor activity in MAPK inhibitor-naïve and MAPK inhibitor-resistant cells containing BRAF or *RAS* mutations.

HY-118916

FTI-2148	Farnesyl Transferase	Cancer
FTI-2148 is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 1.4 nM and 1.7 μM, respectively.

HY-117152

L-threo-Sphingosine L-threo-Sphingosine C-18	p38 MAPK Apoptosis	Cancer
L-threo-Sphingosine is a potent MAPK inhibitor. L-threo-Sphingosine induces apoptosis and clear DNA fragmentation. L-threo-Sphingosine shows anticancer effect.

HY-136310

PIP4K-IN-a131	Others	Cancer
PIP4K-IN-a131 is PIP4K lipid kinases inhibitor, with IC₅₀s of 1.9 µM and 0.6 µM for purified PIP4K2A and PIP4Ks, respectively. PIP4K-IN-a131 exhibits cancer-selective lethality via dual blockade of the lipid kinase PIP4Ks and mitotic pathways.

HY-150927

G12Si-2
Ras Cancer

G12Si-2, an analog of G12Si-1 (HY-150926), is a negative control tool. G12Si-2 is not a covalent inhibitor of the G12S mutant of K-Ras.

HY-118916A

FTI-2148 diTFA	Farnesyl Transferase	Cancer
FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 1.4 nM and 1.7 μM, respectively.

HY-151523

KRas G12R inhibitor 1	Ras	Cancer
KRas G12R inhibitor 1 (compound 3) is a KRas G12R selective covalent inhibitor that exploits the strong nucleophilicity of mutant cysteines and binds irreversibly in the Switch II region of K-Ras. KRas G12R inhibitor 1 can be used in cancer research.

HY-144657

PROTAC SOS1 degrader-2	PROTACs Ras	Cancer
PROTAC SOS1 degrader-2 is a potent PROTAC SOS1 degrader. PROTAC SOS1 degrader-2 decreases the expression of pERK and RAS-GTP level in a dose-dependent manner. PROTAC SOS1 degrader-2 significantly inhibits the tumor growth in vivo.

HY-123952

RTC-5 TRC-382	EGFR	Cancer
RTC-5 (TRC-382) is an optimized phenothiazine with anti-cancer potency. RTC-5 demonstrates efficacy against a xenograft model of an EGFR driven cancer, its effects is attributed to concomitant negative regulation of PI3K-AKT and RAS-ERK signaling.

HY-101494

Temuterkib LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of ERK1 and ERK2, with IC₅₀ of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-113313S1

Aldosterone-d7	Endogenous Metabolite	Cardiovascular Disease
Aldosterone-d₇ is the deuterium labeled Aldosterone. Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level[1][2].

HY-148764

M47	Apoptosis	Cancer
M47 is a small molecule that selectively destabilizes Cryptochrome 1 (CRY1) and increases degradation of the CRY1 in the nucleus. M47 enhances apoptosis in Ras-transformed P53-deficient mouse skin fibroblast lines and enhances life span in p53 knockout mice. M47 can be used in research of cancer.

HY-100627A

APS-2-79 hydrochloride	MEK	Cancer
APS-2-79 hydrochloride is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATP^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.

HY-100627

APS-2-79	MEK	Cancer
APS-2-79 is a KSR-dependent MEK antagonist. APS-2-79 inhibits ATP^biotin binding to KSR2 within the KSR2-MEK1 complexe with an IC₅₀ of 120 nM. APS-2-79 makes the stabilization of the KSR inactive state antagonizes oncogenic Ras-MAPK signaling.

HY-122866

ZT-12-037-01	Ras	Cancer
ZT-12-037-01 is a STK19-targeted inhibitor, has a high-affinity interaction with STK19 protein and inhibits oncogenic NRAS-driven melanocyte malignant transformation. ZT-12-037-01 is an ATP-competitive inhibitor, inhibiting phosphorylation of NRAS (major isoform of Ras family) with an IC₅₀ of 24 nM.

HY-113849

MLS-573151 MLS000573151	Ras	Inflammation/Immunology
MLS-573151 (MLS000573151) is a selective GTPase Cdc42 inhibitor with an EC₅₀ of 2 μM. MLS-573151 is inactive against other GTPases family members, such as Rab2, Rab7, H-Ras, Rac1, Rac 2 and RhoA wild-type. MLS-573151 acts by blocking the binding of GTP to Cdc42.

HY-128590

PHT-7.3	Ras	Cancer
PHT-7.3 is a selective inhibitor of *connector enhancer of kinase suppressor of Ras* 1 (Cnk1) pleckstrin homology (PH) domain (K_d**=4.7 μM). PHT-7.3 inhibits mut-KRas, but not wild-type KRas cancer cell and tumor growth and signaling. PHT-7.3 has antitumor activity.

HY-128350A

FGTI-2734 mesylate	Farnesyl Transferase	Cancer
FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC₅₀s of 250 nM and 520 nM for FT and GGT, respectively. FGTI-2734 mesylate can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.

HY-143588

KRAS G12C inhibitor 35	Ras	Cancer
KRAS G12C inhibitor 35 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 35 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent CN112920183A, compound 3).

HY-143590

KRAS G12C inhibitor 37	Ras	Cancer
KRAS G12C inhibitor 37 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 37 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2018143315A1, compound 65).

HY-143606

KRAS G12D inhibitor 12	Ras	Cancer
KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134).

HY-143594

KRAS G12C inhibitor 40	Ras	Cancer
KRAS G12C inhibitor 40 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 40 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 70).

HY-128350

FGTI-2734	Farnesyl Transferase	Cancer
FGTI-2734 is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀s of 250 nM and 520 nM for FT and GGT-1, respectively. FGTI-2734 can prevent membrane localization of KRAS, hence solving KRAS resistance problem and thwarting mutant KRAS patient-derived pancreatic tumors.

HY-143604

KRAS G12D inhibitor 11	Ras	Cancer
KRAS G12D inhibitor 11 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 11 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 52).

HY-143591

KRAS G12C inhibitor 38	Ras	Cancer
KRAS G12C inhibitor 38 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 38 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129820A1, compound 171).

HY-150054

G12Si-5	Ras	Cancer
G12Si-5 is a covalent inhibitor of the G12S mutant of *K-Ras* (K_i: 26 μM). G12Si-5 binds with the S-IIP domain and suppresses oncogenic signaling. G12Si-5 reduces phospho-ERK level in KRAS G12S mutated cells.

HY-143589

KRAS G12C inhibitor 36	Ras	Cancer
KRAS G12C inhibitor 36 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 36 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021121367A1, compound 1-2).

HY-143598

KRAS G12C inhibitor 42	Ras	Cancer
KRAS G12C inhibitor 42 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 42 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2020146613A1, compound 10).

HY-143599

KRAS G12D inhibitor 8	Ras	Cancer
KRAS G12D inhibitor 8 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 8 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021107160A1, compound 2).

HY-143607

KRAS G12D inhibitor 13	Ras	Cancer
KRAS G12D inhibitor 13 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 13 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 142).

HY-143602

KRAS G12D inhibitor 9	Ras	Cancer
KRAS G12D inhibitor 9 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 9 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 20).

HY-143596

KRAS G12C inhibitor 41	Ras	Cancer
KRAS G12C inhibitor 41 is a potent inhibitor of KRAS G12C. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12C inhibitor 41 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2021129824A1, compound 121).

HY-143603

KRAS G12D inhibitor 10	Ras	Cancer
KRAS G12D inhibitor 10 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 10 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 34).

HY-150054A

G12Si-5 formic	Ras	Cancer
G12Si-5 formic is a covalent inhibitor of the G12S mutant of *K-Ras* (K_i: 26 μM). G12Si-5 formic binds with the S-IIP domain and suppresses oncogenic signaling. G12Si-5 formic reduces phospho-ERK level in KRAS G12S mutated cells.

HY-141477

RM-018	Ras	Cancer
RM-018 is a potent, functionally distinct tricomplex KRAS^G12C active-state inhibitor. RM-018 retains the ability to bind and inhibit KRAS^G12C/Y96D and could overcome resistance. RM-018 binds specifically to the GTP-bound, active [“RAS(ON)”] state of KRAS^G12C.

HY-151287

KRAS inhibitor-20
Ras Cancer

KRAS inhibitor-20 is a small molecular inhibitor of KRas^G12C, the oncogenic mutant. KRAS inhibitor-20 inhibits KRas^G12C with the IC50 value <10 nM.

HY-138295

KRAS inhibitor-10	Ras	Cancer
KRAS inhibitor-10 (compound 11) selectively and effectively inhibit *RAS* proteins, and particularly KRAS proteins. KRAS inhibitor-10 is an orally active anti-cancer agent and can be used for cancer research, such as pancreatic cancer, breast cancer, multiple myeloma, leukemia and lung cancer. KRAS inhibitor-10 is a tetrahydroisoquinoline compound (compound 11) extracted from patent WO2021005165 A1.

HY-15763

Erastin	Ferroptosis VDAC	Cancer
Erastin is a ferroptosis inducer. Erastin shows selective cytotoxicity, targeting cells expressing oncogenic mutants of RAS. Erastin exhibits the mechanism of ferroptosis induction related to ROS and iron-dependent signaling. Erastin inhibits voltage-dependent anion channels (VDAC2/VDAC3) and accelerates oxidation, leading to the accumulation of endogenous reactive oxygen species. Erastin also disrupts mitochondrial permeability transition pore (mPTP) with anti-tumor activity.

HY-145048

SOS1-IN-5	Ras	Cancer
SOS1-IN-5 is a potent inhibitor of SOS1. SOS1-IN-5 is a pyrimidobicyclic derivative. SOS1-IN-5 blocks the activation of KRAS by interfering with RAS-SOS1 interaction, and achieves the purpose of broad-spectrum inhibition of KRAS activity. SOS1-IN-5 has the potential for the research of cancer diseases (extracted from patent WO2021203768A1, compound 4).

HY-13995B

Sevelamer carbonate	Others	Metabolic Disease
Sevelamer carbonate is an orally active and non-calcium-based phosphate binding agent and used for the hyperphosphatemia of chronic kidney disease (CKD)research. Sevelamer carbonate effectively lowers serum phosphorus levels hile having minimal effect on serum calcium or serum chloride levels in vivo. Sevelamer carbonate is considered as an improved, buffered form of sevelamer (HY-13995).

HY-144269

SHR902275	Raf	Cancer
SHR902275 is a potent, selective, and orally active RAF inhibitor targeting RAS mutant cancers. SHR902275 has IC₅₀s of 1.6 nM, 10 nM, and 5.7 nM for cRAF, bRAF^wt, and bRAF^V600E, respectively. SHR902275 shows cell growth inhibition with GI₅₀s of 1.5 and 0.17 nM, 0.4 nM and 0.32 nM for H358, A375, Calu6, and SK-MEL2 cells respectively.

HY-146432

Antitumor agent-60	Apoptosis Raf Ras ROS Kinase MDM-2/p53
Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting *RAS-RAF* signaling pathway and binding to CRAF with a K_d value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.

HY-N10503

Norartocarpetin	Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis	Cancer
Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC₅₀ value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC₅₀ value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells.

HY-120793

CMC2.24 TRB-N0224	Ras Apoptosis MMP	Cancer Inflammation/Immunology
CMC2.24 (TRB-N0224), an orally active tricarbonylmethane agent, is effective against pancreatic tumor in mice by inhibiting *Ras* activation and its downstream effector ERK1/2 pathway. CMC2.24 is also a potent inhibitor of zinc-dependent MMPs with IC₅₀s ranging from 2.0-69 μM. CMC2.24 alleviates osteoarthritis progression by restoring cartilage homeostasis and inhibiting chondrocyte apoptosis via the NF-κB/HIF-2α axis.

HY-12403

Angiotensin (1-7) Ang-(1-7)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease Endocrinology
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

HY-16659

EHT 1864	Ras	Neurological Disease Cancer
EHT 1864 is an inhibitor of Rac family small GTPases. EHT 1864 directly binds and impairs the ability of this small GTPase to engage critical downstream effectors required for growth transformation. The K_d values are 40, 50, 60, and 230 nM for Rac1, Rac1b, Rac2 and Rac3, respectively. EHT 1864 also potently inhibits other Rac-dependent transformation processes, Tiam1- and Ras-mediated growth transformation. EHT 1864 prevents Aβ 40 and Aβ 42 production in vivo. EHT 1864 dependently suppresses the release of migrasomes from podocytes induced by LPS, PAN, or HG.

HY-136265

BC-LI-0186	Aminoacyl-tRNA Synthetase	Cancer
BC-LI-0186 is a potent and selective inhibitor of Leucyl-tRNA synthetase (LRS; LeuRS) and Ras-related GTP-binding protein D (RagD) interaction (IC₅₀=46.11 nM). BC-LI-0186 competitively binds to the RagD interacting site of LRS (K_d=42.1 nM) and has on effects on LRS-Vps34, LRS-EPRS, RagB-RagD association, mTORC1 complex formation or the activities of 12 kinases. BC-LI-0186 can effectively suppress the activity of cancer-associated MTOR mutants and the growth of rapamycin-resistant cancer cells. BC-LI-0186 is a promising agent for lung cancer research.

Cat. No.	Product Name

HY-L077

Anti-Pancreatic Cancer Compound Library

2311 compounds

Pancreatic cancer is a devastating disease with a low overall survival rate. Chemotherapy is the most common treatment for patients presenting with advanced pancreatic cancer. More recently, the era of targeted therapies has generated a lot of interest in discovering better approaches for patients with pancreatic cancer. Commonly mutated genes in pancreatic cancer include K-ras (in 74-100% of cases), p16INK4a (up to 98%), p53 (43 to 76%), DPC4 (about 50%), HER-2/neu (in about 65%) and FHIT (found in 70% of cases). Other genes involved are notch1, Akt-2, BRCA2 and COX-2. These proteins are important targets of target therapies for pancreatic cancer.

MCE offers a unique collection of 2311 compounds with identified and potential anti- pancreatic cancer activity. These compounds target K-Ras, p53, HER2, Notch, AKT, etc. MCE anti-pancreatic cancer compound library is a useful tool for anti-pancreatic cancer drugs screening and other related research.

HY-L145

Antihypertensive Compound Library

408 compounds

The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.

Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).

MCE offers a unique collection of 408 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.

Cat. No.	Product Name	Target	Research Area

HY-P2360

G12 Ras 5-17	Peptides	Others
G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).

HY-P2360A

G12 TFA Ras 5-17 TFA	Peptides	Others
G12 (Ras 5-17) TFA is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 TFA can be used as a control of mutant Ras peptides studies (such V12).

HY-P2361A

S12 TFA
Peptides Others

G12 (Ras 5-17) is a wild-type Ras peptide consisted of amino acids 5-17 (KLVVVGAGGVGKS). G12 can be used as a control of mutant Ras peptides studies (such V12).
HY-P2361

S12
Peptides Others

S12 is a mutant RAS peptide containing the Gly (G) to Ser (S12) substitution. The sequence of the peptide is KLVVVGASGVGKS.

HY-12403A

Angiotensin (1-7) (acetate) Ang-(1-7) (acetate)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Endocrinology Inflammation/Immunology Cardiovascular Disease
Angiotensin 1-7 (Ang-(1-7)) acetate is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 acetate inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acetate acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 acetate blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium.

HY-P3277

KRpep-2d
Ras Cancer

KRpep-2d is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research.
HY-P3277A

KRpep-2d TFA
Ras Cancer

KRpep-2d (TFA) is a potent K-Ras inhibitor and inhibits proliferation of K-Ras-driven cancer cells. KRpep-2d can be used for cancer research.

HY-P3108

Alamandine	Angiotensin Receptor Angiotensin-converting Enzyme (ACE)	Cardiovascular Disease
Alamandine, a member of the renin-angiotensin system (RAS), a vasoactive peptide, is an endogenous ligand of the G protein-coupled receptor MrgD. Alamandine targets to protect the kidney and heart through anti-hypertensive actions.

HY-12403

Angiotensin (1-7) Ang-(1-7)	Angiotensin Receptor Angiotensin-converting Enzyme (ACE) Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease Endocrinology
Angiotensin 1-7 (Ang-(1-7)) is an endogenous heptapeptide from the renin-angiotensin system (RAS) with a cardioprotective role due to its anti-inflammatory and anti-fibrotic activities in cardiac cells. Angiotensin 1-7 inhibits purified canine ACE activity (IC₅₀=0.65 μM). Angiotensin 1-7 acts as a local synergistic modulator of kinin-induced vasodilation by inhibiting ACE and releasing nitric oxide. Angiotensin 1-7 blocks Ang II-induced smooth muscle cell proliferation and hypertrophy and shows antiangiogenic and growth-inhibitory effects on the endothelium. Angiotensin 1-7 shows anti-inflammatory activity .

Cat. No.	Product Name	Target	Research Area

HY-P99278

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody	Inhibitory Antibodies	Cancer
Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.

Cat. No.	Product Name	Target	Category

HY-121532

(-)-Rasfonin	Ras Apoptosis Autophagy	Phenols Monophenols Classification of Application Fields Disease Research Fields Cancer Source classification Microorganisms
(-)-Rasfonin is a fungal secondary metabolite and inhibits small G proteins Ras. (-)-Rasfonin induces apoptosis, necrosis and autophagy in ACHN cells (a renal carcinoma cell line).

HY-W048303

L-Azatyrosine	Antibiotic	Phenols Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Infection Source classification Animals Microorganisms
L-Azatyrosine is an antitumor antibiotic isolated from Streptomyces chibaensis. L-Azatyrosine can restore normal phenotypic behavior to transformed cells bearing oncogenic Ras genes.

HY-16059

Arglabin (+)-Arglabin	NOD-like Receptor (NLR) Farnesyl Transferase Autophagy	Sesquiterpenes Terpenoids Structural Classification Compositae Apios americana Medik. Plants Source classification Inflammation/Immunology Disease Research Fields Classification of Application Fields
Arglabin ((+)-Arglabin), a natural product isolated from Artemisia glabella, is a NLRP3 inflammasome inhibitor. Arglabin shows anti-inflammatory and antitumor activities. The antitumor activity of Arglabin proceeds through its inhibition of farnesyl transferase which leads to the activation of RAS proto-oncogene.

HY-W011269

Eicosapentaenoic Acid sodium EPA sodium; Timnodonic acid sodium	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA)sodium is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid sodium exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid sodium activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid sodium can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-B0660

Eicosapentaenoic Acid EPA; Timnodonic acid	Endogenous Metabolite Histone Demethylase	Ketones, Aldehydes, Acids Classification of Application Fields Disease Research Fields Cancer Neurological Disease Source classification Endogenous metabolite
Eicosapentaenoic Acid (EPA) is an orally active Omega-3 long-chain polyunsaturated fatty acid (ω-3 LC-PUFA). Eicosapentaenoic Acid exhibits a DNA demethylating action that promotes the re-expression of the tumor suppressor gene CCAAT/enhancer-binding protein δ (C/EBPδ). Eicosapentaenoic Acid activates RAS/ERK/C/EBPβ pathway through H-Ras intron 1 CpG island demethylation in U937 leukemia cells. Eicosapentaenoic Acid can promote relaxation of vascular smooth muscle cells and vasodilation.

HY-128553

Antineoplaston A10	Ras Apoptosis Endogenous Metabolite	Alkaloids Piperidine Alkaloids Structural Classification Endogenous metabolite Source classification Disease Research Fields Cancer Classification of Application Fields
Antineoplaston A10, a naturally occurring substance in human body, is a *Ras* inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.

HY-N6796

Manumycin A	Farnesyl Transferase Ras Apoptosis Phospholipase	Antibiotics Other Antibiotics Infection Disease Research Fields Classification of Application Fields Source classification Microorganisms
Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i=1.2 μM), and as a noncompetitive inhibitor with respect to the *Ras* protein. Manumycin A induces apoptosis and exerts antitumor activity . Manumycin A suppresses exosome biogenesis and secretion via targeted inhibition of Ras/Raf/ERK1/2 signaling. Manumycin A is a nSMase inhibitor (EC₅₀=0.25 μM).

HY-116514

(S)-(−)-Perillyl alcohol	Apoptosis Endogenous Metabolite	Terpenoids Structural Classification Other Monoterpenes Labiatae other families Endogenous metabolite Plants Source classification Peucephyllum schottii A.Gray Disease Research Fields Cancer Classification of Application Fields
(S)-(−)-Perillyl alcohol is a monoterpene found in lavender, inhibits farnesylation of Ras, upregulates the mannose-6-phosphate receptor and induces apoptosis. Anti-cancer activity.

HY-N1374

Magnolin	ERK	Phenylpropanoids Lignans Inflammation/Immunology Disease Research Fields Classification of Application Fields Source classification Plants Magnoliaceae Magnolia Liliflora Desr.
Magnolin, a major component of Magnolia liliiflora, inhibits the Ras/ERKs/RSK2 signaling axis by targeting the active pocket of ERK1 and ERK2 with IC₅₀s of 87 nM and 16.5 nM, respectively.

HY-113313

Aldosterone	Endogenous Metabolite	Steroids Classification of Application Fields Disease Research Fields Cardiovascular Disease Source classification Endogenous metabolite
Aldosterone is the primary mineralocorticoid. Aldosterone is a steroid hormone, and it is synthesized and secreted in response to renin-angiotensin system activation (RAS) or high dietary potassium by the zona glomerulosa (ZG) of the adrenal cortex. Aldosterone activity is dependent by the binding and activation of the cytoplasmic/nuclear mineralocorticoid receptor (MR) at cellular level.

HY-N10503

Norartocarpetin	Tyrosinase Ras Raf MAPKAPK2 (MK2) Apoptosis	Flavones Structural Classification Flavonoids Plants Moraceae
Norartocarpetin is a tyrosinase inhibitor. Norartocarpetin has strong tyrosinase inhibitory activity with an IC₅₀ value of 0.47 μM. Norartocarpetin as an antibrowning agent can be used for the research of food systems. Norartocarpetin also has a significant anticancer activity in lung carcinoma cells (NCI-H460) with an IC₅₀ value of 22 μM. Norartocarpetin has antiproliferative effects are mediated via targeting Ras/Raf/MAPK signalling pathway, mitochondrial mediated apoptosis, S-phase cell cycle arrest and suppression of cell migration and invasion in human lung carcinoma cells.

Species:	Human (34) Rat (1) Mouse (1)
Tag:	His (21) Tag Free (1) Avi (3) GST (2) Fc (3)
Source:	HEK293 (16) P. pastoris (1) Sf9 insect cells (3) E. coli (16)

Cat. No.	Product Name	Species	Source

HY-P77781

*HLA-A0301 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77783

*HLA-A1101 KRAS G12D Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77784

*HLA-A1101 KRAS G12D Protein, Human (Biotinylated, HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77785

*HLA-A1101 KRAS G12D Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77786

*HLA-A1101 KRAS G12V Complex Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77790

*HLA-A0301 KRAS WT Protein, Human (Biotinylated, HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77789

*HLA-A0301 KRAS WT Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77782

*HLA-A0301 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77787

*HLA-A1101 KRAS G12V Complex Protein, Human (Biotinylated, VVGAVGVGK, HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P77788

*HLA-A1101 KRAS G12V Complex Tetramer Protein, Human (HEK293, His-Avi)** MHC; KRas; K-Ras 2; KRas2; C-K-Ras; CFC2; K-Ras2A; K-Ras2B; K-Ras4A; K-Ras4B; KRas1; KRas2; NS; NS3; RasK2; GTPase KRas; KI-Ras; RALD	Human	HEK293

HY-P75998

RAB7A Protein, Rat (His)
Ras-related protein Rab-7a; Ras-related protein BRL-Ras; RAB7A; RAB7
Rat E. coli

HY-P7805

KRAS Protein, Human (G12V, His) Ki-Ras; c-K-Ras; KRas2; RasK2; KRas4B; KRas4B; K-Ras4B	Human	E. coli
KRAS Protein, Human (G12V, His) is a 25-30 kDa human KRAS protein with G12V mutation and N-terminal His-tag. K-Ras belongs to the small GTPase superfamily, Ras family.

HY-P7804

KRAS Protein, Human (G12C, His) Ki-Ras; c-K-Ras; KRas2; RasK2	Human	E. coli
KRAS Protein, Human (G12C, His) expresses in E. coli with a His tag at the N-terminus. KRAS G12C is an oncogenic driver mutation in multiple cancer types.

HY-P7805A

KRAS Protein, Human (G13V, His)
Ki-Ras; c-K-Ras; KRas2; RasK2
Human E. coli
HY-P7804A

KRAS Protein, Human (G13C, His)
Ki-Ras; c-K-Ras; KRas2; RasK2
Human E. coli
HY-P76561

RAB31 Protein, Human (His)
Ras-related protein Rab-31; Ras-related protein Rab-22B; RAB31; RAB22B
Human E. coli
HY-P70233

Kras4B Protein, Human (His)
rHuGTPase KRas4B, His; Ki-Ras; c-K-Ras; KRas2; RasK2; CFC2
Human E. coli
HY-P70153

KRAS Protein, Human (G12S, His)
rHuKRas-G12S, His; Ki-Ras; c-K-Ras; KRas2; RasK2; CFC2
Human E. coli

HY-P71619

SYNGAP1 Protein, Human (His) DKFZp761G1421 ; KIAA1938; MRD5; Neuronal RasGAP; OTTHUMP00000064825; p135 SynGAP; Ras GTPase activating protein SynGAP; Synaptic Ras-GAP 1; SYNGAP 1; SYNGAP1	Human	E. coli

HY-P70232

Kras4B Protein, Human (G12C, His)
rHuGTPase KRas4B-G12C, His; Ki-Ras; c-K-Ras; KRas2; RasK2; CFC2
Human E. coli
HY-P70234

Kras4B Protein, Human (G12V, His)
rHuGTPase KRas4B-G12V, His; Ki-Ras; c-K-Ras; KRas2; RasK2; CFC2
Human E. coli
HY-P71260

RHEB Protein, Human (GST)
GTP-Binding Protein Rheb; Ras Homolog Enriched in Brain; RHEB; RHEB2
Human E. coli
HY-P74609

RAB2 Protein, Mouse (His)
Ras-related protein Rab-2A; Rab2A; Rab2
Mouse E. coli
HY-P75993

RAB1B Protein, Human (HEK293, Fc)
Ras-related protein Rab-1B; RAB1B
Human HEK293
HY-P75994

RAB27B Protein, Human (HEK293)
Ras-related protein Rab-27B; C25KG; RAB27B
Human HEK293
HY-P75997

RAB6A Protein, Human (His)
Ras-related protein Rab-6A; Rab-6; RAB6A; RAB6
Human E. coli
HY-P700268

RHEB Protein, Human (sf9, N-His)
GTP-Binding Protein Rheb; Ras Homolog Enriched in Brain; RHEB; RHEB2
Human P. pastoris
HY-P75995

RAB27B Protein, Human (HEK293, His)
Ras-related protein Rab-27B; C25KG; RAB27B
Human HEK293
HY-P75996

RAB27B Protein, Human (HEK293, Fc)
Ras-related protein Rab-27B; C25KG; RAB27B
Human HEK293
HY-P74607

RAC2 Protein, Human (His)
Ras-related C3 botulinum toxin substrate 2; GX; Small G protein; p21-Rac2
Human E. coli
HY-P74610

RAB11B Protein, Human (HEK293, His)
Ras-related protein Rab-11B; GTP-binding protein YPT3; RAB11B; YPT3
Human HEK293
HY-P74608

RAC1 Protein, Human (sf9, GST)
Ras-related C3 botulinum toxin substrate 1; p21-Rac1; RAC1; TC25; MIG5
Human Sf9 insect cells
HY-P76838

CNKSR3 Protein, Human (sf9, GST)
Connector enhancer of kinase suppressor of Ras 3; CNK3; Maguin-like protein; MAGI1
Human Sf9 insect cells
HY-P73741

NRAS Protein, Human (His)
GTPase NRas; Transforming protein N-Ras; NRas; HRas1
Human E. coli
HY-P73919

HRAS Protein, Human (sf9, His)
GTPase HRas; Ha-Ras; HRas; HRas1
Human Sf9 insect cells
HY-P75500

ARHI Protein, Human (HEK293, Fc)
GTP-binding protein Di-Ras3; DIRas3; ARHI; NOEY2; RHOI
Human HEK293

Cat. No.	Product Name